Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.

导出 LinkOut

翻译打印收藏纠错

第一作者： Mariane S,Fontes

第一单位： Oncology Department, Oncoclinicas Group, Rio de Janeiro, Brazil.;LACOG, Latin American Cooperative Oncology Group, Brazil.

作者： Mariane S,Fontes ^[1] ; Daniel,Vargas Pivato de Almeida ^[2] ; Clarissa,Cavalin ^[3] ; Scott T,Tagawa ^[4]

作者单位： Oncology Department, Oncoclinicas Group, Rio de Janeiro, Brazil.;LACOG, Latin American Cooperative Oncology Group, Brazil. ^[1] LACOG, Latin American Cooperative Oncology Group, Brazil.;Oncology Department, Oncoclinicas Group, Porto Alegre, Brazil. ^[2] Oncology Department, Oncoclinicas Group, Rio de Janeiro, Brazil. ^[3] Weill Cornell Medicine, New York, NY, USA. ^[4]

关键词 ADC SN-38 Trop-2 antibody–drug conjugate bladder cancer human trophoblast cell surface antigen 2

DOI 10.2147/OTT.S339348

PMID 36575731

发布时间 2024-09-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

OncoTargets and therapy

2022年15卷

1531-1542页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.

OncoTargets and therapy

相似文献

OncoTargets and therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.

OncoTargets and therapy

相似文献

OncoTargets and therapy

相关期刊

检索历史清除